Patient
P2B-108
completed Phase IIA Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma · State Health Centre Oncology Department (Budapest, Hungary) (Dr. Clarke)
consented 2013-05-01
Adverse events
6
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 6
Grade 1 anaemia with onset in cycle 4 (2013-07-30); assessed as related to study drug (probable); resolved 2013-09-08.
Grade 1 neutropenia with onset in cycle 3 (2013-06-28); assessed as related to study drug (probable); resolved 2013-07-03.
Grade 3 thrombocytopenia with onset in cycle 2 (2013-06-10); assessed as related to study drug (probable); resolved 2013-06-15.
Grade 1 nausea with onset in cycle 2 (2013-06-01); assessed as not related to study drug (not related); resolved 2013-06-04.
Grade 3 leukopenia with onset in cycle 1 (2013-05-24); assessed as related to study drug (probable); resolved 2013-05-29; action: drug interrupted.
Grade 3 pleurisy with onset in cycle 1 (2013-05-19); serious (hospitalization); assessed as not related to study drug (not related); resolved 2013-05-29; action: drug interrupted.
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.